Desperate move or winning formula: BMS to test hep C drug with sovaldi

Save

The trial will test the combination of Gilead and BMS's drugs in 30 previously untreated patients with the most common genotype 1 form of the virus. It will include two arms, each with 15 patients enrolled, with one receiving four weeks of treatment and…